Showing 6,801 - 6,820 results of 30,761 for search '(( 50 ((we decrease) OR (((nn decrease) OR (a decrease)))) ) OR ( 2 step decrease ))', query time: 1.01s Refine Results
  1. 6801
  2. 6802
  3. 6803
  4. 6804
  5. 6805
  6. 6806
  7. 6807

    DN dynamin II (K44A) slows down endocytosis of KCa2.3. by Yajuan Gao (309862)

    Published 2013
    “…<p><b>A.</b> BLAP-KCa2.3 was co-expressed with either WT or K44A dynamin II and cell surface expression of the channel evaluated in triplicate as detailed in the <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0044150#s2" target="_blank">Methods</a> (top panel). …”
  8. 6808
  9. 6809
  10. 6810
  11. 6811
  12. 6812

    The Design, Synthesis, and Characterizations of Spore Germination Inhibitors Effective against an Epidemic Strain of Clostridium difficile by Shiv K. Sharma (1945762)

    Published 2018
    “…To circumvent this problem, a series of cholic acid amides were synthesized and tested against R20291. …”
  13. 6813
  14. 6814

    Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with <i>In Vivo</i> Efficacy in Multip... by Obdulia Rabal (124515)

    Published 2021
    “…Concomitant inhibition of key epigenetic pathways involved in silencing tumor suppressor genes has been recognized as a promising strategy for cancer therapy. Herein, we report a first-in-class series of quinoline-based analogues that simultaneously inhibit histone deacetylases (from a low nanomolar range) and DNA methyltransferase-1 (from a mid-nanomolar range, IC<sub>50</sub> < 200 nM). …”
  15. 6815

    Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with <i>In Vivo</i> Efficacy in Multip... by Obdulia Rabal (124515)

    Published 2021
    “…Concomitant inhibition of key epigenetic pathways involved in silencing tumor suppressor genes has been recognized as a promising strategy for cancer therapy. Herein, we report a first-in-class series of quinoline-based analogues that simultaneously inhibit histone deacetylases (from a low nanomolar range) and DNA methyltransferase-1 (from a mid-nanomolar range, IC<sub>50</sub> < 200 nM). …”
  16. 6816

    Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with <i>In Vivo</i> Efficacy in Multip... by Obdulia Rabal (124515)

    Published 2021
    “…Concomitant inhibition of key epigenetic pathways involved in silencing tumor suppressor genes has been recognized as a promising strategy for cancer therapy. Herein, we report a first-in-class series of quinoline-based analogues that simultaneously inhibit histone deacetylases (from a low nanomolar range) and DNA methyltransferase-1 (from a mid-nanomolar range, IC<sub>50</sub> < 200 nM). …”
  17. 6817

    Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with <i>In Vivo</i> Efficacy in Multip... by Obdulia Rabal (124515)

    Published 2021
    “…Concomitant inhibition of key epigenetic pathways involved in silencing tumor suppressor genes has been recognized as a promising strategy for cancer therapy. Herein, we report a first-in-class series of quinoline-based analogues that simultaneously inhibit histone deacetylases (from a low nanomolar range) and DNA methyltransferase-1 (from a mid-nanomolar range, IC<sub>50</sub> < 200 nM). …”
  18. 6818
  19. 6819
  20. 6820